Sabtu, 29 April 2017

low today

as we near the end of the summer olympic gamesin rio... it's not too hard not to notice that there haven't been as high of an olympicfever among the korean public as previous olympics or other international sporting eventsheld before. is it the huge time difference between seouland rio... or what? why the mediocre olympic fever this time around?

low today, our news feature tonight with hwang hojun. it became a familiar sight in 2002, when koreahosted football's world cup -- massive crowds cheering in the streets of seoul. in fact, the country's enthusiastic cheeringfor its national team during international

sporting events has attracted a great dealof attention around the world. "we are now down to just a couple more daysuntil the summer olympics in rio de janeiro closes out its 16-day run. this is also when the olympic fervor reachesits peak. well, so has been the case in many previoussummer games. what about rio 2016? we hit the streets of seoul to find out howpeople are enjoying this year's games." "i know the games are happening, but stilli don't really feel the excitement. my friends and i barely talk about the olympics.

my family doesn't really watch the games either." "so i've been in korea for three days now,i think, and i kind of was expecting that people would be gathering in public placesand watching some games. but i haven't seen any of that." one particular mainstay for korean sportsfans whenever the national team competes... is fried chicken. and it's perhaps an indicator of this apparentchange in attitude. on wednesday night, the korean men's tabletennis team faced germany for the bronze medal. the match was set for 11 p.m., korea time,yet there were plenty of empty seats at this

fried chicken restaurant in downtown seoul. "the so-called 'olympic premium' isn't truethis year. the number of customers and delivery requestsis practically the same as before the games." twenty-five minutes into the bronze medalmatch,... and still no one had asked to put on the olympics. "trying to earn money nowadays is exhausting. so, i feel like i'm prioritizing my qualityof life over the athletes competing for korea. it's not like their medals will change mylife." the lack of olympic fervor is also evidentin the record-low ratings for the olympic

tv coverage by korea's three main networks. in the past, ratings for the london and beijingolympics were around 20 to 30 percent. as of tuesday, however, the ratings had barelymade 16 percent. one reason for the low viewership is thatfewer people are staying up late to watch the games live, and more are using mobileapps and online platforms to track the results. "for me, it's enough to just watch the highlightson my smartphone in the morning to get the final results. but lose sleep to watch live? that would have a devastating effect on myroutine the next day."

"user traffic has increased about 150 percentduring the olympics. most users are consuming edited clips of matchhighlights. since it's a mobile platform, not many peopleare looking to watch an entire event." low ratings usually translate into low adrevenues, and considering the networks paid the ioc over 40 million u.s. dollars to broadcastthe olympics, many are expecting losses this year for the networks. some have blamed low viewership on the twelve-hourtime difference between seoul and rio. but according to the experts, it's much morecomplicated. they say the combination of the recent economicslump and high unemployment has young people

focusing more on their own well-being thanon entertainment. in other words, the young don't have timefor the olympics. "you could say the reason people are watchingthe games has changed for the better -- it's purely for entertainment and the love of sport. unless it's a match that they're interestedin, people don't watch just because the korean team might beat another country's team. that's not a good enough reason anymore."

low today

this year, we might not hear the late nightcheering next door... or see neighbors celebrating in the streets,...but in two years time that may change... when

the winter olympics come to pyeongchang. hwang hojun, arirang news.

low affect

les biesecker:thank you very much for having me. thank you for the nice introductions. and for thoseof you who are here to see me the second time, thank you for your patience. as a few of youmay know, i had -- i lost an argument with a couple of intervertebral discs in my c spineon april 13, 2012, and was unable to deliver the lecture, although i heard that you gota great lecture. dr. elaine ostrander filled

low affect, in for me about dog genetics. i would haveliked to have heard that myself, actually. but i was horizontal for that day. so what i want to talk with you about a littlebit is some of the work we're doing in genomics and clinical genomics to try and understandthe spectrum of heritability in human diseases

and human traits, including disorders thatsome of you are likely dealing with. so what this is about -- some of you may haveheard this phrase thrown around. there's several phrases that are sort of the phrase du jourhere. they all mean pretty much the same thing. i use the phrase "individualized medicine."some people use the phrase "personalized medicine." some people are calling it "genomic medicine."but the notion is the same, regardless of what word you might choose to use, which isto think about trying to customize or individualize care based on individual risks instead ofpopulation risks. and we are currently in a phase of medicine where, to push it a littlebit, we sort of worship at the altar of the large, blinded, controlled trial. and we dothat because -- not because it's bad, but

we do it because it works, and it allows usto find and evaluate therapeutics in a way that works for large numbers, substantialnumbers, substantial fractions of large populations of people. and that is good. although, i will tell you, in the course ofthis little encounter i had with those discs in my spine, i was on the phone with a colleagueof mine, who, believe it or not, was a lawyer, and he was commiserating with me because he'shad some of the similar problems, and he just went on this long harangue about the anti-inflammatories,or oral pain meds. and he said, "you know, they'll tell you that this medicine worksin 40 percent and that medicine works in 40 percent and then the third medicine worksin 40 percent." and he's lecturing me, "don't

you believe it for a minute, because those40 percent aren't the same people." so here's a lawyer telling me that we should be practicingindividualized medicine. i thought that was pretty hilarious. so what we want to do is acknowledge that,that what he's saying is probably correct, and i think all of us know that from our practices,and we use as much information as we have at our command to try and make those decisionsabout how to apply which treatment to which patient, and we use our intuition, and ourhunches, and our clinical acumen to try and make those decisions. but it would be better,i think, if we had some data that would allow us to direct the treatments toward individualsin a rational way. so we want to do several

things, right? we want to apply the treatmentsto the patient where it's most likely to be efficacious in that patient and where it'sthe least likely to have toxicity or adverse effects. we also would like to begin to move towardtreating and preventing diseases before the patient actually gets sick. and this is alittle bit of a radical notion, and it has a lot of challenges associated with it, butit is a very important goal, and i think that's important in cardiology as well as in manyother fields, like cancer. it won't be easy to do. and lastly, though this isn't a very popularthing to mention, but there are certain times

-- and we, again, use our clinical judgmentto do this all the time in current practice -- but when we have a patient we're takingcare of where the treatment is futile, it's good clinical judgment to stop rendering thattreatment, in most cases. if it's not helping the patient and the disorder is going to progress,why are we doing this, especially, again, if there are adverse effects? and there'ssome great examples now in oncology where the oncologist can identify patients who areextraordinarily likely, essentially certain, to be refractory to certain treatments. andin those cases, it's the wrong thing to do to continue those treatments. and we haveto figure out who these people are. so to do this stuff, all of these things thatwe would like to be able to do with individual

patients, we have to be able to make predictionsabout the medical and physiologic attributes of those patients at the level of the individual,and the large, randomized clinical trial will never get us there. we have to do it a differentway. okay, so what are we looking for? we needthe ability to assay or test some attribute of our patient that defines either the presenceof occult disease or disease that is yet to manifest, future risk of disease, responseto a treatment we haven't yet tried, adverse effects, et cetera. and, you know, truthfully,we do this all the time, right? we use physical signs all the time to detect, primarily, occultdisease. splinter hemorrhages in the fingernails is a sign that, by itself, means essentiallynothing to the patient, yet that tells us

what's going on with that patient's cardiovascularsystem, right? so we're used to this concept at the clinical level, and what genomics isgoing to do is expand that into heritable disease and allow us to make predictions basedon that patient's heritable susceptibility or propensity to develop disease. but predictions is a tough business, and we'redealing with a complex system here, right? the human organism is a complex critter. andi like this quote from albert einstein. i'll read it to you. "occurrences in this domain-- " of course, he's talking about particle physics, right -- "are beyond the reach ofexact prediction because of the variety of factors in operation, not because of any trace-- any lack of order in nature." so we recognize

that the system is complex. we recognize thatwe won't be able to make precise predictions. but that doesn't mean that you can't makepredictions. so that's a nice way of saying this, which was the gentleman in the foreground,niels bohr: "prediction is very difficult, especially if it's about the future." someof you may have seen that. that has been misattributed to our friend yogi berra, but it was actuallyniels bohr who said that. and i just like the picture of the two guys together and thetwo quotes side-by-side, and i think it gives you a nice feel for this problem. okay, so -- and going back to health carepredictions, we can ask the question, "can we do this for traits, for diseases that havea substantial heritable component?" so what

are the tools we need to do that if that'swhat we want to do? so we need some sort of an assay that broadly assesses the risk ofthese traits or diseases. until recently, that was very difficult to do, because thetesting, the genomic genetic testing that we had until recently, was low-throughputand focused, and the clinician had to know what disease they were looking for to orderthe test to determine the susceptibility to the disease. and so that was a very intrinsicallylimiting problem. but now that the technology is changing, we can ask the question in anopen, prospective way with an individual patient, and extract that knowledge that we're lookingfor. all right. so what are we actually talkingabout here technologically? so we have to

do a little bit of genetics here, and so ihave a graph here. this is a theoretical graph that shows on two axes the frequency, whatwe call the minor allele frequency; that is, any position in the genome or in a gene wherethere is a difference, a variation in the population, the less common of the two states,the minor allele. frequency can range from zero -- almost zero to 50 percent. can't bemore than 50 percent, because then it's the major allele, right? so that's the frequencyof some allele in the population. and then we think about a heritable trait, and we canask the question, "if a person has the minor allele, how likely is it that that personhas the trait?" and that, we call "penetrance." and that can range from zero to one. so ifthat variation in every single person leads

to the trait being manifest, the penetranceis one. and if that variation has a very, very low contribution to that trait, and maybeonly 1 percent of people who have that variant have that trait, then that's a low-penetrancetrait. there's a general relationship for variationthat we know in the genome versus traits that sort of hovers in a cloud, if you will, alongan axis between here and here. all right. a lot of you have heard about snps and gwas,genome-wide association studies. what that kind of a study is doing is assessing commonvariation in the population -- so alleles that have minor -- variants in the genomethat have minor allele frequencies, from about 1 percent to up to 50 percent -- and askingthe question, "are those variants associated

with some trait?" and that has been done verysuccessfully for a number of traits, including cardiovascular diseases like atherosclerosis,lipids, blood pressure, et cetera. and you can find these variants, and you can discoverthe relationship between genotype and disease, and this is an incredibly fruitful and productivearea of science. then there's this stuff up here that jean[spelled phonetically] referred to that i have worked on in the past. and these arevariations in the genome that are individually extremely rare variations going down in frequencyto what is essentially one over the population size; that is, variants that are essentiallyunique, and we see that in the population. and these rare variants, many of them canhave very significant impacts on phenotype.

that is, when they're present, 100 percentof the people, essentially, who have that variant have that trait. now, there are -- this cloud exists becausethis stuff down here is stupendously hard to figure out. if a variant is uncommon inthe population and it has a low effect on the trait, statistically it's really hardto find. so this, we are sort of thinking, for all practical purposes, until we can assaythe entire population on the planet, is really unknowable. we just can't figure that out.this, between here and here, so these rare diseases that we currently know about andthese common variants that lead to low-penetrance traits, there is a huge cloud here, and thisis currently unknown, but it is becoming knowable

because of the technological advances thatwe're now seeing. and the notion is, what we have to do in genomics and clinical geneticsand in medicine is to connect these two clouds of variants and understand this full rangeof genomic variation and the relationship between genotype and phenotype in the fullspectrum of frequency to penetrance. okay, so to summarize again, you can thinkof, in general, our current understanding is there's two classes of genomic variation:common variation and rare variation. so common variants are relatively easy now to assayand analyze. these are done -- this is done by what are called snp chips, so chips -- dnachips that assay two million, sometimes upwards of five million different common variationsacross the genome. and then statistical testing

is done to relate those variations with sometrait. and there's -- that's all very straightforward to do. now the statistics are all worked out,and we know how to do that. the problem is, again, it requires large cohort sizes, right?this makes sense, because if the effect of the variant is small, you're going to needa large population of people to find the relationship. that's plain, old-fashioned statistics. youcan't escape from that. so, again, it goes back to this notion of the large trial andaveraging across patients. it is incredibly useful and has illuminated a number of differentrelationships that we didn't previously appreciate, connecting genes and the proteins they codefor with traits and diseases, and has been a real boon to understanding the pathophysiologyof human disease. the problem is, is that

for us. as clinicians, it doesn't necessarilyhelp us with individual patients, because, again, each of these variants is relativelypoorly predictive of phenotype. rare variants, until recently, were nearlyimpossible to assay genome-wide, but now, because of sequencing, they are getting mucheasier to find and generate the actual variants, but it's still hard to analyze them. i'lltalk a little bit about that. the associations, because they're powerful, can require smallernumbers, so that's a good thing for us as clinicians. and what i really like about itis we can then bring this into the clinic and start to think about assaying the genome,the individual patient, and making a prediction about an individual person that is highlylikely to be correct.

okay, so a little bit of background on genes.genes have a number of parts. this is a strand of dna. this dark part here, these green blocksare the parts of the dna that encode for protein. genes have elements within them that controltheir expression, when and how they're expressed. those are called promoters and enhancers.and then there's lots of dna between the genes. that is spacer dna; it used to be called "junkdna," but that's no longer correct because we know all of it has function. so these piecesof the gene are then spliced together. here's an individual gene spliced together. an openreading frame is what makes a protein. the protein is what does the job in the cell. so common variants are, for the most, notin the protein coding parts of genes. and,

in fact, a fair number of them aren't in genesat all. they're in this dna outside of genes. the rare high-penetrance variants that we'retalking about, that stuff in the upper left-hand corner of the graph, turns out almost allof those are in these green blocks, these coding parts of these exons, and the coolthing about that is, even though there's 20,000 genes and 300,000 exons across the entiregenome, this green stuff only comprises about 1 percent or 2 percent of the dna. so if you'reinterested in the high-penetrance, individual prediction parts of genes, you only have tolook at 1 to 2 percent of the dna to extract that information. and the technology that allows us to do thisis incredibly cool. it's very complex, but

you can show the concept here, which is thatwe take dna from the patient, shear it up into little blocks, and then we basicallytake artificial dna that's complementary to those green parts of the genes, mix that withour patient's dna, and it has little beads on it that allow us to extract that dna with,believe it or not, actually a magnet, which is kind of cool, so you magnetically separateout the dna you're interested in, and then that's the dna which represents those greenparts of the genes. then you take each of those pieces of dna and adhere it to a slide,and hundreds of millions of these pieces of dna are added to a slide at one time, andthen that is -- each one of those molecules is sequenced simultaneously in a that's why this sequencing, it's commonly

called "next-generation sequencing." morecorrectly, it should -- it's called "massively parallel sequencing." it's massively parallelbecause you're running hundreds of millions of sequencing reactions all at the same time.and then each one of these sequences is read off of the slide, and then it's fed into thecomputers that analyze those sequences, find which part of the dna, of the genome, theycomprise, lines them up, stacks them up, and reads the base pairs. so sequencing instruments actually look likethis, these nice boxes with the cool glowing blue lights. that makes them really cool,right? and these things are really awesome, right? so you can now sequence a whole genomeor six to eight exomes -- and exomes is just

that 1 percent to 2 percent -- in about threedays. okay? ten years ago, this took -- the first genome took about 15 years to sequenceand cost $1 billion to $2 billion. so now it takes about three days, costs about 10,000bucks for a whole genome. but you can do the green parts, the exome, or the exons, forabout 1,000 bucks or less, which is a stupendous drop in cost, which is starting to make thistechnology comparable in cost to a lot of tests we order on patients all the time. andthat allows us to simultaneously, in a single reaction, in a single assay, evaluate allgenes. and that's the tool we need, from the previous slide, to make these predictionsand assay these genes, again, without knowing what disease the patient has.

all right. this is not all goodness and light,all right? there's some bad news to this stuff too. this is not as easy as it looks. it generatesstupendously large amounts of data. so for every genome we put into one of these instruments,the typical output is about three million variations. so any two of you i were to sequence,i look at your two genomes, you will differ in about three million nucleotides. some of-- most of that is benign variation; some of that is variation that is associated witha disease. the trick is to figure out which is which. nontrivial. so interpreting thisis a huge challenge. we're just scratching the surface of this. a small fraction of itcan be interpreted, and then the glass is half full, the glass is half empty. half emptyis, we can only interpret a small fraction

of it. glass half full is, yeah, but the fractionthat we can interpret is useful. and i'll show you how that is useful. so, as these instruments were being developeda few years ago, a group of us got together and said, "well, you know, the biologistsare using this to understand the biology of genomes. why don't we docs get together andfigure out how we can use this to help take care of patients?" and so we put togethera project called clinseq, which was a translational research project to use genome sequencingin clinical care, clinical research to figure out the relationship with disease and buildan approach to developing this as a clinical assay. so we set up a study. our initial targetwas to recruit 1,000 people into the study.

our initial phenotype was cardiovascular disease.we thought that was a great trait to start with because it has a lot of attributes thatare amenable to this kind of an approach. we know that cardiovascular disease -- atherosclerosis,myocardial infarction susceptibility, hyperlipidemia -- has a high degree of heritability. we allknow that. there are common variants, common variations in the genome that lead to low-penetrancesusceptibility to lipid levels, as well as rare variants that lead to high-penetrancelipid syndromes, other cardiac phenotypes as well. so what we wanted to do was develop a cohortof people who had a range of phenotypes for atherosclerosis, from completely unaffectedto affected, and then assay those patients

by whole genome sequencing. so we did whatwe called "binning," which was we recruited patients into the study based on framinghamrisk scores, 250 each of each of these categories, the framingham risk scores, and one bin ofpatients who have the disease, and we're still recruiting for patients who are affected withatherosclerosis and have had myocardial infarctions. sequence them, and then we do the follow-upstudies. we interpret the variations that we can extract from their genomes, validatethem, return them to patients, and try and start managing these patients based on thesevariants to, again, test the model of individualized medicine. the recruitment was for folks that were between45 and 65 years of age. it was open to any

ethnic group, both sexes. we did want to excludesmokers. in phase i, we did require that they have a primary care physician, recognizingthat we were going to find things in their genomes that would need to be evaluated andfollowed up by their physicians, and so we wanted to make sure they had that in place.people -- and we were looking for people who wanted ongoing involvement in the study. andwe also have set it up so that the patients themselves don't have direct access to thedata. this has actually come to be an interesting issue, which we could talk about if peoplehave questions. so, clinically, what do we actually do tothe folks who enroll in the study? we take only a brief history, because here's the problemwith the genome. we can assay all 20,000 genes,

but no clinician can do a history or a physicalthat evaluates a patient for all 20,000 gene traits. that is just not possible. so whatwe have to do is set this up in a way where we do it iteratively. that is, we start withsome brief phenotyping and history-gathering, bring the patients in, consent them for ongoinginvolvement, and say, "we're going to come back to you after we look at your genome.when we find variations in this, that, or the other gene, we're going to phenotype youfor traits related to those genes, and do it in a directed, iterative way." so the information we gather is pretty minimal,by my standards, to tell you the truth. brief history just related to cardiovascular disease,a family history, a few anthropometrics, electrocardiogram,

echocardiogram, coronary calcium, a prettybroad panel of chemistries, which you can see here, for your reference, and then someresearch samples, dna, rna, and we make cell lines for the patients. okay. so here we have these patients who areinterested in doing this. we have the genomic or exomic data sets on the patients. we havethe baseline phenotypic data. how do you actually go about, then, using these data to find conditionsin patients? so we set out to do some pilot studies. and this is one of three of our earlypilots. and what we decided to do was to screen a set of patients for cardiovascular traitsthat were not related to the reason why they enrolled in the study. and this is a reallyimportant caveat. we enrolled patients for

atherosclerotic heart disease, and what we'redoing here is assaying them for something other than atherosclerotic heart disease. so we had an exome set of 572 patients thathad been exome sequenced, and we asked the question, "how many of these patients havea gene variant that predisposes them to have either a cardiomyopathy or a rhythm -- cardiacrhythm disorder." so we did a literature search, searched the textbooks, and came up with 41genes that have been found to be related, highly related to cardiomyopathies of varioustypes, and i listed those here. some of the folks in the room, i'm sure, are more familiarwith some of these traits than am i. and then a number of rhythm disorders, like atrialfib, long-qt syndrome, et cetera, and asked

the question, "how many patients have variantsin those diseases?" so when you take the exomes, again, you findenormous amounts of variation. remember, this is 572 people. and it is -- i think it is63 genes. yeah, 41 plus 22. so you take just short of 600 folks and 63 genes. how manyvariations do you find in their genomes? about 1,200. right? so that's an average of twovariants, two genetic variants per person, in a set of traits that we know are not commontraits. these are rare disorders. so what that's telling us is that there is much morevariation in the genome than there are pathogenic causative mutations for these traits, andthat means that only a small subset of them are actually causative. so which ones arethose? and that's the trick of the interpretation

at genome-scale interrogation. so what we do is what we call filtering. soyou take those 1,200 variants, and you begin to look at them and ask questions about them,and basically do exclusions if those variants have attributes that make you think that theyare not pathogenic. so, of course, one of the first ones is, if we can look and validatethe sequence technology, the values, the quality values that are coming off the instruments.if we're not convinced about that, we can eject the variants. frequency's a big one. so we use frequency.and this is a little bit of circular reasoning, but it's practical, and it works, which isthat if a variant -- so let's take any one

of those genes for those traits. if a singlevariant for that trait is present in the cohort at a frequency that is substantially higherthan the trait itself -- so let's say the trait affects one in 1,000 people, all right,and let's say there's 100 variations that cause that trait. you know that any one geneticvariation that can cause that trait is a subset of that one in 1,000. if any variant is presentat a frequency that's as common as the trait, you know it can't cause that trait, becauseotherwise the trait would be much more common than it is. you have to be a little carefulwith that, but that's how we can start filtering. that pushes out an enormous number of variants. there are certain types of variation thatare more likely than others to actually be

pathogenic. so we can exclude some of theones that aren't -- that don't have those attributes. and then it gets down to sortof brute force, good old-fashioned pulling up the literature and analyzing the casesof the patients who have been reported to have those variations or very similar variations,and determining, based on clinical judgment, if those reports of causation are, in fact,true. and that's a challenge, but works quite well. all right. so when we look at 63 genes and572 people, what do we find? well, turns out you find pathogenic variants. so about 1 percentof these patients have pathogenic mutations in one of these genes. one of these was dilatedcardiomyopathy. this is a gene that's called

phospholamban, and this exact variant hasbeen found to be present in patients with dilated cardiomyopathy. hypertrophic cardiomyopathy,two different patients, each with their own unique variation. these are -- for those ofwho aren't familiar with this, these are standard mutation nomenclature. this means there'sa stop mutation in the gene, so that gene protein product is truncated prematurely.that's a severe mutation. this is a mutation -- remember how there were the little greenblocks in the gene that were spliced together? this is a mutation of one of the sequenceelements that causes that splicing not to occur, so the gene is never put together correctly.and this is a change in an amino acid, so this is what we call "missense variant" ina gene. that has been shown to cause this

trait. then some of the rhythm disorders.we had three patients who had cardiac rhythm disorders. variants have all been describedin several families, and one of which i'll tell you a little bit more about. okay, so then we go back and, again, lookat the patients, and do this in an iterative way. so for the cardiomyopathy patients, whenwe went back and pulled their echoes, they did not have current evidence of cardiomyopathy.okay? so that can mean one of two things. either we're wrong and these variants do notactually cause these diseases, even though they're published as being causative variants,or what we have done is exactly what we set out to do, which is to find disease susceptibilitybefore the disease manifests. right?

when we look at the family histories, we findseveral of these individuals have a striking family history of unexplained cardiac, that could be attributed to a number of things, and those diagnoses are hard toassess, because these are secondhand reports of disease and death. but we were quite impressedat how many people have relatives who have unexplained symptoms and deaths. and thisis that last patient i mentioned, who was a very interesting patient in our study. thisis a lady who enrolled at the young end of our age eligibility, late 40s, and she hashad ongoing problems with unexplained syncopal episodes. she has a left bundle branch blockthat is not explained by a known coronary artery or other cardiac disease. she has,on our electrocardiogram, a clearly abnormal

qt corrected interval. and she also has achild who also has had episodes of unexplained palpitations. so here is a patient who cameinto our study to be enrolled for atherosclerosis, doesn't have atherosclerosis, but instead,when we sequence her, we find a variant that i think is highly likely to be pathogenicfor a serious cardiac rhythm abnormality, and we have diagnosed this disease in a patientwho didn't know that she had it. so what is going on here? this is actuallypretty radical stuff, because it flies in the face of how, essentially, all of us wereclinically trained. so what we did is we took a cohort that was not selected in any wayfor the presence of cardiomyopathy or dysrhythmia, or for family history of sudden death, right,because that's how we normally do genetics.

we try to go out and find patients who havethese rare phenotypes or have family histories of these disorders, and we sequence them.we're not doing that here. we're taking unselected patients and just screening their genomesand asking the question, "what tiny subset of this population has this trait?" we sequencedall genes and then selected the genes retrospectively to look at and analyze, and there was no indicationfor doing this testing in these people. and what we found is that more than 1 percentof our cohort have apparently pathogenic genes in these diseases that we consider to be raremonogenic forms of non-atherosclerotic cardiovascular disease. so, again, this was done without a chief complaint,without a history, without an exam, without

any clinical testing to suggest a disorderwas there, without a family history, and ordered every test -- ordered tests for every genein the genome. and i can tell you -- and i think most of you would say the same thing-- if i had even suggested doing such a thing when i was in my clinical training, they wouldhave practically hit me with sticks. you don't do that. what i was trained to do is thati only ordered tests when i knew that the patient had an indication for the test, thati understood what the test was for, and that the alternative outcomes of the test wouldchange the management of the patient i was taking care of. that's what i was taught todo. we are completely throwing that head over heels and saying the exact opposite. so thisis a radical thing to do. but, again, if we're

serious about wanting to do individualized,predictive medicine, we do have to be willing to throw these things overboard and try somedifferent approaches. so, again, this is contrary to everything we've been taught and is a newway to think about how to practice medicine. the interesting thing is, when you stop andconsider our old model, our old model works, but it's kind of perverse, in a way, isn'tit? what we're basically telling people is, "you know what? we are not going to understandyour disease until you're either already sick or people in your family have died. untilthat happens, leave us alone, because we're not going to take care of you." that's ourcurrent paradigm. and you have to ask the question: is that really what we should bedoing? and there's good reasons why we practice

medicine the way we do. and i'm not here tosay that the chief complaint, the history, the exam, the differential diagnosis is useless,because you and i all know that it is absolutely not. it is essential. it will always be'll always be useful. that skill set will always be important. but now it's not theonly way to do it. there is another way to do it. all right, so, getting back to the originalfocus of the study, let's think about dyslipidemia. so this is not a surprise, right? if you recruitpatients into a cohort and you want to study atherosclerosis and you select for patientswho have disease, you darn well better find people who have dyslipidemias, because weknow that dyslipidemias cause atherosclerotic

heart disease. so here's another participantin our cohort at the higher end of the age scale, 65-year-old female. she was diagnosedwith high cholesterol at the age of 25 years. she was very, very well-managed. and you cansee her numbers were in good shape. although, she is clearly suffering from this dyslipidemiaand has a stupendously high coronary calcium score, although she has not yet had an mi. so here's a lady that we evaluated and wefound that she had a pathogenic mutation in the low-density lipoprotein receptor, whichis a very well-known cause of hypercholesterolemia. and we then talked to this patient, and itturns out she had several family members who had said, "oh, yeah, i think some of my relativesalso have high cholesterols." and we went

through the family and identified four otherpeople who have this trait as well. and this is a really interesting phenomenon, becausewhen i talk to practicing physicians, internists, family practitioners, pediatricians, theywill tell me -- and they're very comfortable being frank with me. that's what the diplomaticscall it, a frank and honest exchange. and they say, "i don't need no freaking genetictest to tell me if my patient has hypercholesterolemia." right? you can do that biochemically. theydon't need it. well, actually, i would say that we do needit, and here's why. for every patient we've discovered that has a genetic cause of a dyslipidemia,we have found, by looking at them and their relatives, between four to eight patients,relatives of them, who have hypercholesterolemia

that is either undertreated -- either completelyundiagnosed or significantly undertreated. and yes, it is true that you don't need toanalyze the genome or the proband to understand that they have hypercholesterolemia, becauseyou can diagnose that, you can treat it, and you can manage it perfectly fine. but we canactually leverage this, because what happens is we can identify multiple other individualsin the family, and that marginal cost of identifying those other people is very, very small. andwhat i'm beginning to understand is, i think, actually, the genomic or the genetic resultforces us and our patients, because it occurs to the patients at the same time, to ask aquestion, "oh, this is a genetic trait, and it's a simple genetic trait. we understandexactly how it's inherited. so, doc, who else

in my family could have this?" and then thedominoes start falling. and, in fact, i think what genomics is doing is forcing a conversationto occur that we are currently ignoring. all of us are trained to take care of the patientin the office. our colleagues in family practice are, arguably, a little better at this thanmost of us -- pediatricians, internists, ob-gyns, et cetera, are -- because we need to startthinking about the family as the patient. there are more patients than one. and including this family, because here thisgrandson, if i remember correctly, was 10 years old and had wildly abnormal cholesterol.and, as some of you may know, the american academy of pediatrics has now recommendedinstitution of statin therapy for children

with familial hypercholesterolemia, not garden-varietyhypercholesterolemia, but familial hypercholesterolemia, starting at age eight, because it is clearthat this lifetime burden of cholesterol is what leads to the buildup of atherosclerosisover time. and this lady's calcium of 1,700 is because she wasn't diagnosed until herthird decade of life, partly attributable to that. and so we need to start treatingthese people much earlier. in fact, we thought this was so clever, but, of course, when wego into the literature, it turns out in several scandinavian countries they have these wonderfulsingle-pair health care systems and public health systems where every person who getsa diagnosis of familial hypercholesterolemia, a public health nurse is sent to that person'shome. they get a family history. then they

go back to the unified medical record systemthat they have; they pull up all their relatives. they go to their houses, and they bring theminto the clinic, diagnose them with familial hypercholesterolemia, and treat them. so they'vebeen using this for about 10 or 15 years, and it works, and they have a very low incidenceof this trait in the population now. okay. okay. so i've told you about two examplesof how we can use genomics clinically. and so we've diagnosed these six cardiomyopathies,nine dyslipidemias. we've also gone through this cohort and asked the question, "how manypeople in this study have cancer susceptibility syndromes?" as some of you may know -- andi think you've had a lecture on cancer genetics already -- there are a number of inheritedcancer susceptibility syndromes where individuals

in these families have an extremely high rateand early onset of cancers. and we, again, did the same 572 people, and eight individualsin those families have an early onset cancer syndrome, and interestingly, only half ofthem were known at the time that they enrolled in this study. and half -- the other halfwere individuals who had either negative family histories, because the family was small or,in the case of several of them, they had hereditary breast and ovarian cancer gene mutations inthe family, but just by chance, these families had a preponderance of male births insteadof females, so there just weren't that many people to manifest. and, again, that getsto that notion of, "we're not taking care of you until you have the disease or yourrelatives start dying of the disease, and

we can find them prospectively." two patients in the cohort have malignanthyperthermia susceptibility syndrome, which is a very important trait, and good, easymedical interventions to eliminate and reduce the risks of that phenotype. three patientswith a peculiar form of neuropathy that's supposed to be rare, that i can't explainwhy it's so common in our cohort, but there it is. and we've also defined one patientwith an occult metabolic disorder that is -- was previously thought to only affect we know it can affect adults as well. and really here, we're just scratching thesurface. this is a decent amount of people. so, again, 500, 600 people. five percent ofthese people have an occult or unrecognized

rare disorder that we thought only affecteda few families here and there but, in fact, is scattered throughout the population ata significant level. and i would actually ask all of you to consider, for those of youwho are in active practice, if you have 2,000 or 3,000 people in your practice and we sequencethem, these data would suggest that 5 percent of those patients, so 50 of your patientsin your practices right now, have diseases like this. and, for the most part, we probablydon't know about that. that's a concerning thought to me. and, again, we're just scratchingthe surface, so really, there's more than that in there. and while clinical sequencing,routine clinical sequencing is not indicated yet, it's going to be soon. you're going tostart seeing patients who have this done,

and we're going to be able to find this. so there's lots of other traits. this is onlya small fraction of genetic traits. there's hundreds of other dominant diseases in humansthat we are going to start going through. pharmacogenetic data can be extracted fromexome and genome sequencing that will allow us to begin to better select drugs, and sopatients who, for example, have a rare variant in a gene that gives them a myopathy fromatorvastatin, we can find that. we communicate that to patients and providers. those drugscan be avoided. as well as all of us have mutations for which we are heterozygous carriersthat have reproductive risks for our descendents, and we should consider that as well.

okay. so this all look really easy, right?i love this picture. [laughter] there's so much unsaid. what i really likehere is you can just barely see in the background all these guys just sort of standing around,and i just can't imagine how annoyed those guys are. all the hard, hard, awful work that went intomaking that beach ready for this guy to sort of prance on with the photographer in frontof him. he makes it look easy. all the hard work has been done before he even got there.and there are a lot of criticisms to this notion of individualized and personalizedmedicine.

so there are some statistical analyses thatsay that heredity is not as good as we think it is at predicting these traits. and thisis an evaluation of identical twins that suggests that our power to do this may not be quiteas high as we think it is. and one of the big reasons for that is, remember that penetrancegraph i showed you? all of those data on penetrance and variation are based on ascertaining rarefamilies. so rare families are selected for the attribute, that when they have this singlevariation, they manifest this disease, which means they probably have some other geneticattributes that make the disease highly likely to be manifested in those families, and thenif you go outside of those highly penetrant families, that what you will see is that thepenetrance of the same variant will drop off,

and so that we may be overestimating that,and that will make our predictions not as strong as we think. we've been dealing with these kinds of problemsfor a long time, though. all of us are used to this, right? we have, in almost all testswe do, a significant probability of false positive results. i've told you, in sequencing,you know, we found more than 1,000 variants in these cardiomyopathy and rhythm genes,and all but six of them were probably benign or unlikely to be pathogenic. in every clinicalpathology test we do, the same thing is true. we use normal ranges, statistical normal rangesthat mean that at least one out of 20 of every test that we do has a false positive justby statistical variation, right? the famous

chem-20 that we order, the odds are prettygood that one of those 20 values is out of whack; just for statistics, not for pathology.and certainly in imaging -- my goodness. we do coronary calcium scores by ct scanning.the rate of false positives in incidental findings in ct scanning is more than 5 percent.plenty of false positives and abnormal findings there. so the next question is, there's a lot ofchallenges for geneticists and for clinicians. are patients ready for this? what is goingto be involved in sitting in a room and talking to a patient about a whole genome test? so,again, genome generates enormous numbers of results, millions of variants. we know, fromclinical experience, it can be a challenge

to communicate one test result to a patientin the clinic. can you imagine talking to them about three million? not even we have to figure out how to cope with this information overload, because that's-- we are swimming in data here, and you cannot bring that into clinical practice. so we'regoing to have to develop new approaches for how we use those data, how we parse them out,how we roll it out to patients over time. and to do that, we need to know what the patientsthink, what they want, and how they use it. so we're studying our participants in clinseqalso to understand how they view the information and what utility they are making about it. so we did what's called qualitative interviewing,open-ended questions to ask patients what

it is that they're looking for, what theyexpect, how they imagine using that. and what we found was two basic clusters of answersto these very open-ended questions. first was -- and this is a wonderful thing aboutbethesda and the nih when we recruit patients in -- patients, these people are really altruistic,and it is absolutely amazing to me how willing these people are to help us understand whatwe're trying to study, even if it doesn't benefit them. they also, though, are equallyinterested in their own health. they believe that they will -- we will find and that theywill receive from us information about their genomes that will allow them to change somethingabout their health care that will help them or their family members. and what's importantabout this -- and this is important methodologically

here -- this is not asking people, "wouldn'tit be interesting to think about having your genome sequenced?" these are people who you'reactually bringing in, and they have to put their arm out, and we take the blood, andwe're doing it. so this is the real thing, and this is what we can really expect peopleto want to do. we also assess their preferences of what they'llwant from exome and genome sequencing at their baseline enrollment and then following theconsent, and then gave them four scenarios for what kinds of classes of results we mightfind and evaluated them on that. and what was interesting, these are self-selected,very interested, eager folks. nearly all of them said they wanted to learn their results.six of them, interestingly enough, were uncertain

about it. even signing up for this study,they weren't sure they wanted their genome results returned to them. they were a littleanxious about what that might mean. they were interested in using it for prevention, andthey felt they were very committed to the notion that they -- having -- them havingthis information would better equip them to either prevent or manage diseases when theydid manifest. there were also some comments about preventive measures that could be implementedby their docs, and then also using the results to change their environmental exposures, theirdiet and exercise, et cetera. about a third of the patients -- a third ofthe population were just curious. it's really -- there's an intense curiosity about ourheritability, about our families, about our

genomes. and these people are of the opinion,"all knowledge is positive." i think that's a really interesting thing, because i wouldbet that every clinician in this room would say, as i would say, that's just not is not the case that everything i can find in all these genomes will be a positive thing.there are things that we can learn that will be wrong. there are things we can learn thatwe will understand there's nothing good we can do about. not all information is positive,yet the patients hold stupendously highly optimistic views of this, and that's an issuewe're going to have to deal with in matching the optimism of patients to the reality ofthis testing. about a third of them wanted the informationbecause they wanted to understand something

either about a trait that they thought wasfamilial and in their family history, or things they wanted to use to transmit to their childrento help their children plan for their futures. and some of them actually came to the studywith a specific condition in mind, and that may be the explanation for why we're seeingsome rare disorders perhaps a little more commonly than we ought to, is a very subtleform of self-selection, is people having this vague but potentially correct feeling that,"you know, there's something going on in my family, and i think you guys can figure itout." and we are then stumbling across those traits. most of it was related to heart disease,again, which is appropriate with the focus of our study. but it may be more general thanthat, and i think that's an interesting thing

to consider. so, again, they're very enthusiastic aboutlearning all range of results, even results that we would say are of uncertain clinicalsignificance. the patients are interested in that and desire that. they do recognizethe distinction among the types, even though they're generally enthusiastic, and they wantthese, what we call, actionable results, genomic results that they can take to their doc anddo something with. knowledge of the patients. again, if you recruitfrom bethesda, you're going to get a knowledgeable and sophisticated group of folks, and theyhad very high levels of knowledge pre- and post-counseling, so they have a long geneticcounseling session, 45-minute session, where

we explain to them what the sequencing isand what it is not. and we -- even though they came in highly educated, there was anincrease in understanding about the power and the limitations of genomics pre- and post-counseling,so that is an important part of it. so the big picture here is i want to challengeyou. i'm a very -- i'm very proud, and i think i'm pretty darn good at phenotyping patients,but i also recognize that i am not -- i am far from perfect at it. and when i sequencea patient's genome, i learn things about my patient that i didn't know before i sequencedit. and i can figure out things that i'm pretty sure i would have never figured out withoutthe genetic data. and i think, because we have only had our diagnostic abilities tofind disease in the past, we rely on that

exclusively, but that doesn't mean that that'sthe only way that we can do this. i think we practice a lot more trial-and-errormedicine than some of us would like to admit. again, that's all we can do, and so we dothe best we can. we have good data to try and tailor medicines and treatments to patientsbased on their attributes, but we're not that good at it. we can do better. our abilityto currently predict disease onset, disease susceptibility, the severity, and the courseof the disease; we would also like to be able to predict that in patients. efficacy andside effects of treatment is, again, limited and is ripe for improvement. and the way to think about this: is genomicsgoing to perfectly solve all of these problems?

no way. but the other way to think about itis, in many respects, we're not as good at this -- nearly as good at this as we wouldlike to be. and even if we can improve it only a little bit in all of these attributes,that would make an enormous difference to medical practice. so, for sure, there is a lot more work thatneeds to be done. we have to do an enormous amount of work to really tighten up this relationship.we have to be able to precisely predict genotype -- predict phenotype from genotype and knowthe limitations of those predictions. we have to develop and test approaches to pre-symptomaticmanagement. we really don't have ways right now, effective approaches to managing a patientwho has hypertrophic cardiomyopathy gene mutation

before they have hypertrophic cardiomyopathy.we need to figure out how to do that. and we have lots of work to do to build the infrastructureand methods for managing and disseminating and using this information with patients andin our health care records. lot of arguments about whether we should orshouldn't do this, and some people are really critical of it. and the truth is, i thinkthose arguments -- that's now water under the bridge. this stuff is out there. genomescan be ordered clinically, and you will start seeing patients in your practices who havehad this kind of testing done, and that may be for reasons completely unrelated to yourcare of your patient. for example, you may be taking care of an adult who has been sequencedbecause they have a child with autism. right?

so when we do sequencing for things like autism,we usually sequence the kid and both their parents. you sequence the parents, you'regoing to find this other stuff whether you want to or not. we're going to have to learnhow to work with it. so it's coming, and not to mention the factthat there's 1,000 people in metropolitan washington who have been sequenced in clinseqnow. some of those may end up in your practice as well. so we have a lot going on, and weare going to have to figure out how to use these genomes clinically, and these patientsare there. there are other downsides here. genetic was really fun. we had a -- nih has a science in the cinema series, and they screened, ontuesday night -- or wednesday night, the movie

"gattaca" over at the afi in silver spring.good -- pretty darn good movie about predictive medicine and discrimination. we have to thinkabout genetic discrimination. we have passed a law called the genetic information nondiscriminationact that addresses some of these concerns, but it has not completely been put to rest.and we really, again, have to struggle with this notion of prediction, and so is geneticsgoing to be able to predict these things, or are we going to end up like these guys?right? here's a mode of prediction that isn't all that respectable anymore. and i wouldactually suggest that genetics is going to do much better than this. but other -- quotei like about predictions is, "the groundhog is like most other prophets; it delivers itsprediction and then disappears."

so, for better or worse, i think us genomicspeople are here to stay. i think we're going to be a thorn in the side for a while. buti think this stuff is going to work, and it's going to expand. we're going to build it out.and we'll be able to predict what's going to happen to our patients before it happens. so i'll stop there, take your questions. andthank you for your attendance. [applause] any questions? yes, sir. male speaker:[inaudible] look at the other side of the coin. in other words, if there's a very strongfamily history, and the individual doesn't

have a disease, is there something protectiveabout their sequence and not only the fact that they don't, or is it related to environmentalfactors? [inaudible] in other words, looking at it from a, "why don't they?" kind of thing[inaudible]. les biesecker:fabulous question. and that gets to this notion of the penetrance. that's exactly what you'reasking about. and there's two levels of that. the first is, absolutely, it's harder to figurethat out. we call that genetic modifiers, when it's other genes that modify the traits,right? and, you know, we sort of know that. sort of our intuition tells us that what you'resaying is true, and we see that when two families come together, family that has a high incidenceof some trait or character, and when they

marry into another family that is maybe geneticallyvery different from them, you can see that trait disappear in the descendents, and that'sexactly the phenomena that you're talking about. the other one is that we're actually -- there'sa great study going on called the centenarian study, and what they're doing is sequencingpeople who have lived to the age of more than 100 years. and the notion will be that thosepeople will have genetic variants that are uncommon in the rest of the population, andthose variants allow them to live into their 11th decade, and so it's a great question.and people are working hard on that right now. and environment is always important.always, always. i like to say it's the -- i

get the -- when i talk to people about thisin social situations, i always get what i call the "uncle walter story." the uncle -- "myuncle walter -- " and, you know, when i get this story, they have at least one hand ontheir hips, right, when they tell me. "my uncle walter ate bacon and eggs for breakfastevery single morning and smoked his cigar after dinner, and he lived to be 600 -- " youknow. people love telling those stories, and there are people who have those protectivealleles. and, you know, frankly, that'd be a good thing to know about. female speaker:idea about the costs? les biesecker:costs. okay. i gave two numbers for cost,

but you should be very skeptical of thosenumbers. those are research costs, okay? so my cost for doing a whole genome sequencein a research context is about $10,000 for an exome, and i think it's currently $850.when that is rolled out clinically, as you're well aware, costs go up because there's alot of things you have to do when you do clinical testing that you don't have to do when youdo research testing, and it makes it significantly more expensive. you can buy from at leastone commercial company that is selling clinical whole genomes. i believe that actually theirretail cost -- and you can order that today for about 10,000 bucks. so you can get retailgenomes for that price today. and people are ordering them, patients who have severe intractablecancer. some of you may have caught that series

in the new york times this past week. patientswho are having whole -- actually, they get two genomes done. they have their normal genome,their peripheral blood genome, done, and then they have their cancer genome done, and theycompare the cancer cells to the noncancerous cells to figure out what's going on in thecancer. so they actually have two of them done -- 20,000 bucks. male speaker:is rna done, too? les biesecker:say it again? male speaker:rna sequencing. les biesecker:and there's rna sequencing, and there's proteomic

analyses, so there's lots of these -omicsthat we can begin to think about doing. but i think you should think about this in the$1,000 to $10,000 range, is where this testing will be, which is a lot of money. we can'tpretend that that's cheap. but, again, it is in the realm of other medical tests thatwe do all the time, medical tests that can't tell us, in fact, as much as we can learnabout a patient from a genome, in some ways. so it's now come down to where you can startto begin to think about this, and you're going to start seeing it in practice. male speaker:those two patients who had the malignant hyperthermia, did they gave a clinical [inaudible], is thatwhat they [inaudible] to these studies?

les biesecker:great question. great question. so those two people, if i remember correctly, did not haveany hint in either themselves or any relative of malignant hyperthermia. one of those twomutations i'm absolutely sure is correct. it's on a panel of the 20 most common mutationsthat cause malignant hyperthermia in european-derived persons on this planet. it's a very commonmutation. it's rock solid. i will also, though, tell you that there is a third person in ourcohort who does have a family history of malignant hyperthermia. male speaker:[inaudible] medications to stay away from? les biesecker:yeah, so malignant hyperthermia is most commonly

caused by -- i think it's isoflurane. arethere anesthesiologists here? i think it's isoflurane and succinylcholine are the triggeringagents. and, of course, then the antidote, the treatment for that is dantrolene. andso these patients, we recommend simply that they wear a medic alert bracelet and haveit in their chart that they have malignant hyperthermia susceptibility. this costs nothing.the treatment really costs essentially nothing. and that if they do go into surgery, thatthe anesthesiologist has a vile of dantrolene sitting there and watches that patient's temperaturein the or, and if the temperature starts to go up, then you know. but the third patient is interesting. we havea guy in the cohort who absolutely has a very

strong family history of malignant hyperthermia.we sequenced him, his whole genome, whole exome, and he does not have a mutation inthe gene. in fact, he has a variation that we showed doesn't cause malignant that's a very important thing to recognize about whole exome sequencing, is that it isnot 100 percent sensitive. i mean, what of our tests are, right? but we have to remember,we use the word "whole" genome sequencing, and we use the word "whole" exome sequencing,and that's just a little bit of a fib, because it's not whole; it's not 100 percent. andso we know that that person, we missed it, even though we know he has it. so the onethat had the family history, we didn't find the variation. the two where we found a variation,they didn't have a family history. and again,

that sort of conflicts with how we're currentlypracticing medicine and genetics, when we require those two things to happen togetherand they don't. yes, sir. male speaker:so could you speak a little bit to your opinions -- oh, [inaudible] mic. les biesecker:yeah, i don't think you need it. i like that. male speaker:could you speak a little bit to your opinions on who should own individualized genomic informationand should have access to it?

les biesecker:so how i think the information needs to be managed is, i think the ideal system wouldbe what i call a two-key system. the information i think of as more sequence is a health careresource; it's not a test. if we think about a whole genome sequence as a test, it gets-- you get tied up into knots because you can't figure out what the heck to do withit. it's too many results to analyze. it's too many results to turn to a patient. it'sjust too much of everything. so what we have to do is take a step back and say, "this isa resource; it's not a test." and the patient will have this done for some reason or haveit done to them because of some reason in a relative. and that resource, then, becomesa part of their health care record or resources.

and then when that person has a need for someinformation from their genome, they and their clinician will have the ability to accessthat, if that both agree that that's a proper thing to do. and so i would envision a partnershipbetween the patient and the clinician where if they are in agreement about it, you useit, and if they're not in agreement, you don't. and it stays safe and secure and is integratedinto our health care system in a way that makes sense with our current practice analysis,because i am not one of these people who likes to go around saying that genetics is goingto revolutionize medicine, because what i've found is that most people actually don't likerevolutions. they're really kind of messy things. and let's try and evolutionize medicineinstead of revolutionize it, and use these

data in ways that makes sense with what wecurrently know how to do and can insinuate it into our practices in a way that's usefulto us as clinicians and where we know what we can do with our patient, and the patientswant it and perceive it as useful and perceive it as necessary, and then go forward thatway. maggie [spelled phonetically], behind you. male speaker:if the genome sequencing is repeated, let's say, at five-year intervals, how accurate,that is to say, how reproducible is it? les biesecker:great question. now, here's your classic, again, glass half full, glass half empty good, quality genome sequencing or exome

sequencing is between 99.9 percent and 99.99percent accurate. impressive number, glass half full. then you say, "okay, how big isthe genome again?" the genome is about three billion nucleotides, and so you can say, "that's,then, how many errors?" that's hundreds of thousands of errors. so those errors willcome up. the error rates in the models for analyzing them are constantly improving, sothat number will actually go down over time. but the dominator is so big that even verysmall error rates can have significant implications. for that reason, we are currently doing thingsin a way that all of our sequence data are generated in a research sequencing laboratory.and then if we are going to use any of those data to do anything to a patient, they arecompletely -- the variant that we're interested

in using for clinical care is completely replicatedin another testing setting to make sure that the two results are the same from the twodifferent methods. and that, then, dramatically lowers the error rate. but when you considerthe genome as a whole, there are errors in it. anytime you assay anything that big andyou're less than perfect, which we always are, there's going to be errors. that's agreat question. then that gets also into the whole questionof mosaicism. and we have this lovely fiction that every nucleated cell in our body hasthe same genome in it, right, because they're all identical. well, actually, it's not true.there's mutations that occur within different parts of our bodies, and there's variationwithin us. and we now know that that can cause

a number of diseases. cancer is the most extremeexample of somatic mutations, right? that's

low affect

where there's hundreds of mutations in a cellor a tissue. but we know, actually, that extends down to much finer grades of variation andcan cause a number of other traits and diseases. so great question. thank you all very much for coming.

Jumat, 28 April 2017

girls sexual

welcome to "indiana newsdesk." the indiana coalition against the indiana coalition against sexual assault hasn't been sexual assault hasn't been operating for months, and operating for months, and advocates worry that means those advocates worry that means thosedealing with sexual assault

girls sexual, dealing with sexual assault aren't getting the help they aren't getting the help they need. need. incasa shut down in june after incasa shut down in june after it was unable to pay overdue

it was unable to pay overdue taxes dating back to 2012. taxes dating back to 2012. the coalition has a court the coalition has a court appointed receiver who will appointed receiver who will attempt to restructure its attempt to restructure its finances. finances. what does that mean for sexual what does that mean for sexual assault survivors in the assault survivors in the meantime? meantime? >> kristen pulice sat in front

>> kristen pulice sat in front of her computer thinking. of her computer thinking. >> i was shocked. >> i was shocked. i thought it was a travesty. i thought it was a travesty. >> shock from losing her job >> shock from losing her job over the summer hasn't worn off. over the summer hasn't worn off.that's when incasa suspended that's when incasa suspended operations and laid off all operations and laid off all staff. staff. now the only access that the

now the only access that the public has to the coalition is public has to the coalition is through its website. through its website. it features only an announcement it features only an announcementabout the organization's about the organization's closure, and a place to donate closure, and a place to donate money to help with the financial money to help with the financialshortfall. shortfall. pulice can't stop thinking about pulice can't stop thinking aboutwhat that could mean for sexual

what that could mean for sexual assault survivors. assault survivors. >> my fear is that if we are not >> my fear is that if we are notable to bring it back, that the able to bring it back, that the voice of sexual assault will voice of sexual assault will once again be just a whisper. once again be just a whisper. it has always been a quiet voice it has always been a quiet voicebehind larger issues such as behind larger issues such as domestic violence and we need to domestic violence and we need tohave a strong voice for sexual

have a strong voice for sexual assault here in the state of assault here in the state of indiana. indiana. >> according to the centers for >> according to the centers for disease control, indiana is the disease control, indiana is the second worst state for rape, second worst state for rape, among high school aged girls. among high school aged girls. incasa provided training to incasa provided training to service providers and law service providers and law enforcement that showed them how

enforcement that showed them howto respond to sexual assaults. to respond to sexual assaults. it connected survivors like it connected survivors like malia crosby with resources to malia crosby with resources to help them heal. help them heal. >> it was so instrumental in my >> it was so instrumental in my own healing journey that it was own healing journey that it was almost like grieving a loss for almost like grieving a loss for something to be gone. something to be gone. it's just -- it's detrimental to

it's just -- it's detrimental tosurvivors. survivors. you know where do we turn for you know where do we turn for services? services? i think there's a big gap in i think there's a big gap in what's available for us. what's available for us. >> crosby says without incasa, >> crosby says without incasa, there's no statewide, one-stop there's no statewide, one-stop shop for survivors to turn to in shop for survivors to turn to inthe event of a crisis.

the event of a crisis. some counties are trying to pick some counties are trying to pickup that slack, but she says it's up that slack, but she says it'snot as effective. not as effective. >> vigo county is handled >> vigo county is handled through the domestic violence through the domestic violence shelter but people don't know to shelter but people don't know toturn there. turn there. >> the closing of incasa also >> the closing of incasa also has service providers like

has service providers like legacy house worried. legacy house worried. >> this is our group room. >> this is our group room. >> the counseling agency works >> the counseling agency works with children and adults. with children and adults. helping them to cope with trauma helping them to cope with traumathrough therapy and art. through therapy and art. >> and our wishes for peace in >> and our wishes for peace in his life and relief from the his life and relief from the anxiety so he can sit and just

anxiety so he can sit and just be like the peaceful tree he be like the peaceful tree he created on this canvas. created on this canvas. >> legacy house works with >> legacy house works with survivors of violence and sexual survivors of violence and sexualassault. assault. the executive director michael the executive director michael hurst says it's important not to hurst says it's important not tolump those issues together. lump those issues together. >> domestic violence is family

>> domestic violence is family violence, and yes, it violence, and yes, it involves -- it typically involves -- it typically involved gender against the involved gender against the other jenner. other jenner. but sexual response has other but sexual response has other issues. issues. the response from the treatment the response from the treatment stand point is much different stand point is much different than the responses when you are

than the responses when you are working with somebody who has working with somebody who has been engaged in some -- been been engaged in some -- been involved of chronic, domestic involved of chronic, domestic abuse over the course of a long abuse over the course of a long period of time. period of time. >> hurst worries the absence of >> hurst worries the absence of incasa will be especially incasa will be especially noticeable during the upcoming noticeable during the upcoming legislative session.

legislative session. the coalition spent much of its the coalition spent much of its time on the third level of the time on the third level of the state house advocating for bills state house advocating for billsthat gave sexual assault that gave sexual assault survivors more power and survivors more power and protection. protection. >> i'm reading what the >> i'm reading what the different legislators are different legislators are thinking about doing and working

thinking about doing and workingwith them as best as i can to with them as best as i can to help inform what they are doing, help inform what they are doing,but, again, we are a service but, again, we are a service provider and so it's very provider and so it's very difficult to stay focused on the difficult to stay focused on thepolicy development when you are policy development when you are in the process of serving 1200 in the process of serving 1200 unduplicated clients over the unduplicated clients over the course of the year.

course of the year. >> state representative kristina >> state representative kristinahale says she's committed to hale says she's committed to leading the fight against sexual leading the fight against sexualassault in the state house. assault in the state house. she plans to file several bills she plans to file several bills during the upcoming session, during the upcoming session, relating to the statute of relating to the statute of limitations and sentencing limitations and sentencing guidelines for rape, but sexual

guidelines for rape, but sexual assault is just one of many assault is just one of many issues she has to tackle. issues she has to tackle. >> i think not having a >> i think not having a respected advocate in the state respected advocate in the state house, you know, that's not house, you know, that's not politicized, that's really just politicized, that's really just about doing good things for about doing good things for people, and victims here in people, and victims here in indiana, that voice is going to

indiana, that voice is going to be missing. be missing. i'm not certain that funding i'm not certain that funding will necessarily be affected will necessarily be affected negatively. negatively. where the funding goes and how where the funding goes and how it gets spent could be affected it gets spent could be affected and that could have implications and that could have implicationsfor services. for services. >> most of incasa's funding

>> most of incasa's funding comes from a federal rape comes from a federal rape prevention and education grant. prevention and education grant. two other groups, and the two other groups, and the indiana campus sexual assault indiana campus sexual assault primary prevention project also primary prevention project also receive a portion of that money. receive a portion of that money.hale says in order for the state hale says in order for the stateto dedicate the resources to dedicate the resources necessary to fight sexual

necessary to fight sexual assault, incasa needs to reopen assault, incasa needs to reopen or a new not for profit needs to or a new not for profit needs tobe created to fill that role. be created to fill that role. that's exactly what pulice has that's exactly what pulice has been thinking. been thinking. even after losing her job, she even after losing her job, she remains hopeful because she says remains hopeful because she saysthe fight against sexual assault the fight against sexual assaultis far too important for incasa

is far too important for incasa to be dissolved. to be dissolved. >> incasa's doors are closed but >> incasa's doors are closed butthe entity still exists and the entity still exists and there's a lot of people that there's a lot of people that want it to stay. want it to stay. >> there is no timeline for >> there is no timeline for incasa's possible recovery. incasa's possible recovery. that's up to the court and the that's up to the court and the appointed receiver.

appointed receiver. reporter barbara harrington reporter barbara harrington joins us now to talk about what joins us now to talk about what we can expect in the coming we can expect in the coming months. months. so how bad is incasa's financial so how bad is incasa's financialsituation? situation? >> well, joe, that's exactly >> well, joe, that's exactly what the court appointed what the court appointed receiver is tasked with trying

receiver is tasked with trying to figure out. to figure out. her name is debra daniels. her name is debra daniels. she's combing through incasa's she's combing through incasa's finances to see if they can finances to see if they can reopen. reopen. we heard that there's a lot of we heard that there's a lot of support to get this organization support to get this organizationback up and running. back up and running. >> we heard in the story

>> we heard in the story representative hale will fire representative hale will fire several bills regarding -- file several bills regarding -- file several bills regarding sexual several bills regarding sexual assault. assault. what she hopes to change? what she hopes to change? >> she has an extensive list of >> she has an extensive list of things she hopes to accomplish things she hopes to accomplish this legislative session. this legislative session. the first one, her first

the first one, her first priority, is coming up with a priority, is coming up with a definition for consent. definition for consent. that's something state of that's something state of indiana doesn't have right now, indiana doesn't have right now, and she says it's really and she says it's really essential to have that essential to have that definition. definition. it will help in prosecuting rape it will help in prosecuting rapeand sexual assault cases.

and sexual assault cases. hale also wants to break down hale also wants to break down barriers that could possibly barriers that could possibly prevent people from reporting prevent people from reporting instances of sexual assault. instances of sexual assault. so she's introducing a bill that so she's introducing a bill thatwill allow those 18 and older will allow those 18 and older who are still on their parent's who are still on their parent's insurance plans, when they insurance plans, when they receive treatment for sexual

receive treatment for sexual assault, the explanation of assault, the explanation of benefits will go to that benefits will go to that 18-year-old, that young adult, 18-year-old, that young adult, instead of their parents. instead of their parents. right now, the explanation of right now, the explanation of benefits goes to their parents benefits goes to their parents which could cue them in that a which could cue them in that a sexual assault has taken place. sexual assault has taken place. >> i assume that would deter a

>> i assume that would deter a lot of people, because kids lot of people, because kids don't want to tell their parents don't want to tell their parentsabout that. about that. it's hard. it's hard. >> exactly. >> exactly. well, you know, a lot of these well, you know, a lot of these instances go unreported and a instances go unreported and a lot of kids done want their lot of kids done want their parents to know about this.

parents to know about this. now, hale is also working on two now, hale is also working on twoother measures that deal with other measures that deal with prosecution. prosecution. the first deals with the the first deals with the criminal code. criminal code. if you remember last year, if you remember last year, legislators made some changes. legislators made some changes. one of those that dealt with the one of those that dealt with thesentencing guidelines for rape.

sentencing guidelines for rape. it dropped from six years down it dropped from six years down to three years, hale wants to to three years, hale wants to change that back. change that back. she wants it to be six years. she wants it to be six years. she also wants to increase the she also wants to increase the statute of limitations for statute of limitations for prosecuting rape from 10 to 15 prosecuting rape from 10 to 15 years. years. so a lot on her plate.

so a lot on her plate. >> and just really short, does

girls sexual

>> and just really short, does she think she has the support of she think she has the support ofher other legislators. her other legislators. >> she says she thinks she has >> she says she thinks she has support o

girls on sex

hi guys, i am raghunath from gyankakshtv and in this prank let's see how kolkata reacts when we drop a sex toy in front of them. so, if you like this video, don't forget toshare with everyone you can and comment your ideas for our other videos. and do subscribe our channel.

Kamis, 27 April 2017

erectile dyfunction

impotence erectile dysfunction because you getthe blood there to to achieve an erection and maintain an erection and sothat's an important and useful piece of information for my patients that come inand tell me you know when i use viagra can have an erection but you know ican't do without it that's important to me that tells me that we need to work oncirculation and i'm also concerned about

erectile dyfunction, blood sugar 15 percent of people witherectile dysfunction have undiagnosed diabetes so that's incredibly importantthat's a very strong message to your body that we want to interpret andreally work on that diabetes that blood sugar issue because if you have abnormalblood sugar swings that can affect your

mood which can affect your ability toperform it can also affect your circulation oftentimes i refer todiabetes as a disease of the cardiovascular system because it causesoxidative damage what that means is that when your blood sugar spikes high itdamages your cardiovascular system in circulation becomes more difficult andyou can also develop atherosclerosis which is the building up of blacks arethe hardening of the arteries and so that's an incredibly importantunderlying cause and while some men may not want to live if they're unable tohave an erection to me as a physician the most important thing even moreimportant than having an erection is

gonna be i wanna have you live in 2009and have to your hundred and have a long healthy fulfilling life three bloodsugar disease free of cardiovascular disease and probably being that hornyold man at ninety that can still perform right that's that's what that's whatmost men i think one and so this is what i'm gonna help you with today so oneimportant thing to do if you're starting to have erectile dysfunction is the payattention did it start suddenly or has it been something that's been graduallycoming on if it's a sudden change important things to ask yourself are yousomething changing your life is there an emotional component because while mostmen may not want to admit it there's a

very emotional part to having anerection and if you're under severe stress youjust lost her job if you're in an unhappy relationship then you may not beable to maintain or achieve an erection in that situation and one way that youcan differentiate that is when you wake up in the morning do you have anerection because that's a physiologic process that often happens with men andso if you're able to wake up in the morning with an erection but unable toperform later with your partner or if you're able to have an erection inmasturbation but not have an erection with your partner that tells me thatthere's something going on in terms of

stress but also maybe stress hormonesthere could be a physiologic component to it but we'll take a different courseof treatment and ways of approaching that then i would for someone who has acirculatory issue or maybe prostate tissue other concerns like that where itwould be a different treatment groups so if you have a sudden onset and nothingchanged your feeling great and your relationship or just whatever whoeveryour sexual partner is you have to have a relationship right but if that hasn'tchanged stresses ok nothing suddenly hashappened then it is important to go see your physician to get a full check now idon't want to scare you but a sudden

onset of inability to have an erectionwe're concerned about nerve issues nerve damage concerned about possible cancer is asmall incidents but as a doctor i always think worse case scenario and i want torule out those big bad things before i feel really comfortable treating onherbal level right and so sudden onset of erectile dysfunction pay attention istheir situation will change if not you go in and see your physician and getsome moderate than to rule out some of these big bad causes as well as some ofthe other causes could be kidney issues which is also an issue with circulationit could be fire road issues people with

thyroid disease slow fire aid that cancause erectile dysfunction and as i said blood sugar issues will all these cancontribute to that and so now let's focus on one of the most common causesof erectile dysfunction is gonna be people so it's been comingon gradually over time definition of erectile dysfunction is atleast 25% of the time that you're trying to initiate sex either the inability toachieve interaction are you able to achieve interaction but unable tomaintain it and that doesn't count if you're drinking 25% of the time thatdoesn't count alcohol can impair one's ability to have an erection so thatwould be a whole nother issue to treat

but if it if it's not any sort of drugor alcohol use as twenty-five percent of time are unable to do that or more thanone dealing with an erectile dysfunction and so then the next step would befiguring out what the causes so unable to get an erection in the morning andunable to perform now i'm thinking more circulatory issues and so what we wantedto generally if you are a patient coming in to see me i'd want to do some bloodwork and i'd want to check things like your thyroid might want to check yourblood sugar and want to check your cholesterol and i'll talk to learn aboutcholesterol because it's not the big bad thing that everyone's telling you it iscluster also incredibly important and

it's actually a key part of thistreatment but i still wanna know where the levels are and part of that would beif you're grossly cholesterol deficient if you're honest statin drugs and yourcholesterol levels are abnormally low that can be a major issue in yourhormone production including your testosterone because cholesterol is aprecursor for all of your hormones at that base building block to make all ofit and so if you're low it can be an issue with depression it can be an issuewith hormones you might be experiencing fatigue for people that are admitted tothe hospital for depression if they see that the cholesterol levels areabnormally low then the sort of thing

under protocol is to screen them forsuicidal depression because it's recognized the mainstream medicine atlow cholesterol can have that much of an effect on the body as well as yourhormones people with low cholesterol often have fertility issues as well andso that's something that's going to be really important so i'll check yourblood sugar right i wanted blood cell count and just make sureyou're not an emic make sure that there's no infections going on prostatitis can be an infection that cancause problems there's a whole lot of things to look for and then what we wantto do is if we've gone through all of

that and let's say your blood sugaryou're fasting blood sugar is maybe in the nineties or higher that's a sign ofsome blood sugar dysregulation and so that means that we're going to startdoing some of the nutritional interventions both dietary so avoidingrefined carbohydrates so things like breads and pastas also sugars obviouslyno white sugar staying away from the cookies all of those things can be areally important step and for some men it may be a choice of do i want to havemy cookie use cookies you know but that it really can be bad do you want to livewith diabetes and erectile dysfunction or do you want to be healthy energeticand sexually vital so that that's an

important reason for some people that'sthe thing that makes them change their lives so many continuing with this sortof work up that i do with patients the next thing that we do is making somebasic dietary changes and then also if there's a situation issuer and thinkingthere's chronic stress there in their fifties they've been working i'm worriedabout their stress hormones and maybe their testosterone level sometimes willtest for testosterone somebody can just tell someone comes in and they'rereporting a lot of symptoms of low testosterone and in general low andregions which are some of your sex hormones a group of hormones the numberone thing that you can do and i tend to

have people i create a treatment planthat says here's the low-hanging fruit is the obvious one that is going to makea difference for most people then ok well let's we've tried that we've gotthat foundation on board here at step 2 345 of what else we can do that's goingto continue to refine it down and create a customized treatment plan for you andyour specific message that your body is trying to tell you number one thing isstarting with supporting healthy cholesterol so i want you to start witheating 12 eggs that might seem like a lot herethe couple reasons why that's going to be helpful but 12 eggs a day and ideallyi want you to space it out throughout

the day because it's gonna hit a coupledifferent targets for you one i want them to be runny eggs or eggthat's because it's going to be more bioavailable in terms of getting thatpromotional precursor that's in those egg yolks and it's full of nutrients ifyou get a good organic free-range egg or if your neighbor down this street haschicken they always have a sign up for sale get those eggs is going to be a nicebright orange color the yolk is gonna stand up when you crack it you don'twant to get that you can buy the grocery store shelves really thin and light paleyellow color is that some guys have all

the nutrients that you need and it mightbe actually pro-inflammatory you want an anti-inflammatory support for healthycholesterol healthy fats in your body to be a good healthy 812 of those a day nowpart of it that's going to do is going to be supporting the hormonal supportand not for most people is gonna make a huge difference the other part of thatis going to be hearing 12 exit day that's a lot of food into your body andthat's an excellent source of protein so it's going to be replacing we're gonnabe taking away some of those sugars some of those refined carbohydrates that areprobably part of your diet and very hard if you've been eating the standardamerican diet if you were raised on you

know pancakes for breakfast peanutbutter and jelly for lunch and then pasta for dinner at a lot of impotencecarbohydrates and carbohydrates turn into sugar in your body most people maythink i don't understand why blood sugar issues i don't need any sweet stuff outeven like that but they're eating chips and bread and pasta in all these thingsthat just turns in the sugar in your body so it's gonna be helping withmaintaining a level blood sugar by getting small protein snacks throughoutthe day and it's also be giving them hormonal support so that's the numberone tip that i can give you in terms of improving your erectile performance interms of being able to achieve and

maintain an erection so if that doesn'tmake a difference and we want to start thinking about other issues do you havethat i just have issues do you chronically suffer from diarrhea or constipation gas or bloatingand that is suggesting that your body isn't able to absorb the with a foodthat's coming into your body and so then we need to look at ok is there a food allergy is that aproblem we might want to look at an elimination diet or a lot of folks whomight just want to start with digestive enzymes so taking digestive enzymes withyour food especially if you've had your

gallbladder removed you need to betaking a digestive enzyme that has ox bile and it because your body is able toproduce the bile in the quantities that it did with a with a functionalgallbladder and so when you need the pile to break down fats and absorb fatemulsifier them is what we call it medical language and so what you wantedto make sure that you can't they just depends i'm so that you can absorb allthose nutrients there could be in the eggs and then the rest of your diet aswell as especially those healthy fats and cholesterol and you may see a lot ofother movement in your body what i expect to see and what i see what a lotof patience when we're working it

underlying cause is they lose weightthey feel more vital their energy is improved life is better and it's notjust because you're waking up in the morning ready to engage in some funactivities with your partner so that's it's a it's a complete life changed thenext thing that we want to work on is if it continues to be an issue excellent do it you looking to dosomething else or if you just want to do the full treatment plan all at once thenext things we want to do is focus on blood sugar regulation as well ascirculation and so in doing that will make sure that you have all of thevitamins and minerals that your body

needs for healthy circulation andhealthy cellular function and so what that means is oftentimes doing a goodfoundation all multivitamin and also increasing your calcium and magnesiumchromium vanadium all these things i is helpful because it is targeted towardsthe cardiovascular system so it's going to help with circulation if there's ablood sugar issue maybe adding in so some chromium some sweetie is theproduct that we do if you have diabetes or if you're close to diabetes doingboth of those things that's going to be a foundational part of the protocolmaking sure that your digestion is on board if you if you're having thosesymptoms of that just've issues

constipation diarrhea gas bloating thenadding in some digestive enzymes as well increased essential fatty acids i talkedabout the importance of facts healthy fats for hormonal production and also beanti-inflammatory inflammation can cause a lot of issues with circulation and sowe want to reduce inflammation as well now if you're a man and your son to getolder and having erectile dysfunction we also want to focus on the prostatemaking sure to make sure it's not an infection but if it's an infection ifit's been nine prostatitis adding in a prostate support something which has sawpalmetto and it at a very robust dosing when i treat people for prostatitis beeni'm prostatitis they normally will see

improvement within one month oftreatment and so that's going to improvement in terms of course if you'rein free force of urination stream frequency of urination and also willstart to see improvement in terms of the erectile dysfunction if that was playinga component because if you have prostatitis it can also cause erectionsto be painful and that's gonna be even if you're not aware of it a psychological deterrent for havingerections additionally you know the next layer of treatment for that will besupporting the hormone side of things so especially anyone living in westernsociety at some point almost all my

patients i see you have some level ofadrenal fatigue i can going you'll see more talks about that so when i go intoit too deeply essentially it's when your stress hormones have been stressed outfor too long and if you were to look at a chart showing how to make all of yourhormone production it starts off with cholesterol and sugar pregnenolone andthen goes down and shows all of your different hormones in your body makestestosterone estrogen dhea cortisol a whole bunch of different hormones in soall of these together if you've been using too much cortisol which is astressful then you're stealing all of the buildingblocks for that you have enough to make

testosterone and so do the hormonalsupport which is also going to help maybe some of the psychological factorsthat can be playing a role if you have too much stress if you're just feelingtoo tired to feel arousal to feel desire than treating the stress the adrenalfatigue can be a huge issue and men something to pay attention to for thisis my one thing about this for your wife especially if you've had childrenespecially if she works sometimes the psychological component can be becauseyou're being turned away enough times and no one likes rejection and so it'sbecause your wife is tired and has adrenal fatigue you might want to gentlytalk to her about supporting her energy

now i recommend starting thisconversation with baby look he seemed like you really tired and i really wannahelp don't even talk about this expert but most of my patients one of the sideeffects that they see side effects of my female patients of treating theiradrenal fatigue issues is increased libido increased desire and so if that'sa psychological component for you of knowing that when you make an attemptto engage in sexual activity with your partner and she turned you down she'sbecoming more of a life partner raising children perhaps building a homewhatever sort of partnership you have but not an object of sexual desireanymore and so you can change that by

helping support her and then the wholemessages that she's getting for her body so in terms of also supporting her moralsupport besides the adrenal and of things which oftentimes all tree eitherwith herbs either the hype of pituitary hypothalamic formula as well as the malehormonal support formula which actually for erectile dysfunction would probablybe the place to start and less high stresses and issue the male hormonesupport formula would be an excellent one for that in terms of the protocolthat we've been talking about so number one to start with the ex easy to do can improve a lot of things for younumber to making sure that that question

is on track they are having digestive issues thatyour body's not giving you a message saying hey something's going on downhere is what we're trying to do is underlying cause i'm not trying to maskthe symptoms which was what would happen if you are using a prescription drug youmight have an erectile dysfunction because you have undiagnosed diabetes inyour body's trying to tell you hate this is going on let's work on it and try andimprove it but if you mask by taking a drug than your body's gonna have tospeak louder to get your attention and then it might be that you become insulindependent diabetes that you go into a

diabetic crisis that you have kidneyfill all of these side effects of diabetes because you don't listen to thefirst message and so we don't want to suppress the symptoms we want to listento him and address the symptoms and so that's that's the foundation part ofthis so that justin and then making sure that you have all the nutritionalprecursors that your body needs so that healthy body brain and heart pack isgoing to be important for that as well as adding in some of the hormonalsupport on the next layer so that hgh use complex as well as an adrenalsupport something like the good herbs male hormone supporting sure and thenmaking sure that there's the

psychological issues as well are dressedat home making sure that the settings right right so making sure that youryour partner is well supported that any other outside stressors that might beaffecting you are are recognized and addressed and thatwere able to support you in not only having a healthy sex life but enjoyingfully all of your life would be amazing if you could listen to your body for onesymptom and improve and change your entire life and that's what we do withnaturopathic medicine so if you want to start this protocol if you want tochange not only your sex life but your entire life then go to take yoursupplements dot com now and one of our

representatives are going to help youget started they're going to give you a call backand help you create a personalized plan for you based off of the things thatwe've talked about today i'm dr. megan

erectile dyfunction
Saunders and I are excited to work with you to change your life and improve your health. I do not make anyone in and I am heretoday to talk to you about impotence erectile dysfunction now or you can visit As your reference.

car rentals sydney cheap

hi i'm nathan just one of jucysawesome crew so you want to know what licenses we accept in australia well so long as you are 18 or over...